Catalent Inc (NYSE: CTLT) shares jumped more than 13% Tuesday after the company announced fourth quarter and full year 2017 results. Catalent provides delivery technologies and development solutions for drugs, biologic, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The stock is up almost 50% year to date. 

The company reported revenue of $616.9 million, an increase of 16% from $532.2 million reported in the fourth quarter a year ago. For fiscal year 2017, Catalent reported revenue of $2,075.4 million, also a strong increase of 12% comparing to the $1,848.1 million recorded last year.

"We're pleased with our performance during the fourth quarter, where we recorded double-digit organic revenue growth and segment EBITDA growth on a constant-currency basis across all three of our reporting segments," said John Chiminski, Chairman, President and Chief Executive Officer of Catalent, Inc. "Fiscal year 2017 was strong across many fronts with financial performance above our long-term outlook, significant levels of free cash flow generation, and the completion of two strategic acquisitions, Pharmatek and Accucaps, both of which are already creating value for the company and our shareholders."